companydata.dkcompanydata.dk

Vericel Denmark ApS: Financial statements 2022

CVR: 19740986

Source: annual report 2022, Danish Business Authority

01/01/2022 – 31/12/2022

Vericel Denmark ApS (CVR 19740986) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -121,528 and a net result of DKK -121,724 compared with DKK -122,292 the year before. Equity in the 2022 report amounted to DKK 6,594,829. The solvency ratio was 99.6%.

Gross Profit
DKK -121,528
Profit/Loss
DKK -121,724
Equity
DKK 6,594,829
Total Assets
DKK 6,620,596
Employees
0

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2022--122 t.-122 t.6.6 mio.0
2021--122 t.-122 t.6.7 mio.0
2020--83 t.-83 t.6.8 mio.0
2019--33 t.-34 t.6.9 mio.0
2018--86 t.-91 t.7 mio.0

Official annual report

View the official annual report directly on the page with a Pro subscription.

Keep an eye on Vericel Denmark ApS

Get notified instantly about new financial statements, ownership changes, management changes and status changes.

Set up monitoring

Events in 2022

Vericel Denmark ApS: The 2021 annual report is outJun 24, 2022

Vericel Denmark ApS has published its annual report for 2021. Gross profit came to DKK -121,591, and the net result was DKK -122,292.

About Vericel Denmark ApS

Vericel Denmark ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 1996. The company is registered under the industry Anden finansiel formidling i.a.n.. The company was previously named AASTROM BIOSCIENCES DK ApS and GENZYME BIOSURGERY ApS. The management consists of Joseph Anthony Mara Jr. The company is owned by Vericel Corporation. The company has 0 employees (2015). In 2025, the company reported a gross profit of DKK -128,481 and a net result of DKK -128,481 compared with DKK -109,464 the year before. Equity in the 2025 report amounted to DKK 6,241,335.

Source: annual report 2025, Danish Business Authority